About this paper
In the year since SAS hosted the first Clinical Trial Data Transparency Forum, we have seen a notable shift in organizational culture and the tenor of the discussions, from uncertainty to questions to vision to action.
Out of an initial atmosphere of doubt, there is now widespread agreement that greater access to patient-level data is a good thing – good for science, good for business and good for humanity. Now it’s just a matter of determining the best way to go about it.
This paper summarizes discussion on the topic with life sciences leaders at the fourth installment of the Clinical Trial Data Transparency Forum, sponsored by SAS in October 2014.